Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Dolastatin-10. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.34 |
| ▸ | PTPRB | P23467 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 2/20 | 0.32 |
| ▸ | CTSD | P07339 | 6/20 | 0.32 |
| ▸ | CTSE | P14091 | 6/20 | 0.32 |
| ▸ | BACE1 | P56817 | 4/20 | 0.32 |
| ▸ | REN | P00797 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dolastatin-10 SCHEMBL18793204 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL13135112 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL12016480 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL16730776 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL13378458 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL23387006 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL6423272 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL22126284 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL22126283 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR | |
| Dolastatin-10 SCHEMBL14583139 | 1.00 | SSTR2 (0.40) | SSTR2CYP3A4FOLH1PTPRBTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11500 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105061-A1 | ANTIBODY-DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | WO | claimed |
| EP-3766510-B1 | CONJUGATES AND PRODRUGS FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CENTRE NAT RECH SCIENT (FR) | 2026-05-13 | — | — | EP | claimed |
| US-20260115305-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| EP-4731263-A1 | BIO-CONJUGATES FOR ONCOLOGY | RDP Pharma AG (CH) | 2026-04-29 | — | — | EP | claimed |
| US-12605457-B2 | Modified EGFR antibody with reduced affinity, drug conjugate, and use thereof | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2026-04-21 | — | — | US | claimed |
| US-12605458-B2 | Antibody-drug conjugate having acidic self-stabilization junction | SYSTIMMUNE, INC. (US) | 2026-04-21 | — | — | US | claimed |
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CELLIS AG (CH) | 2026-04-02 | — | — | US | claimed |
| US-20260083866-A1 | COMPOSITIONS TARGETING ENDOTHELIAL CELLS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-03-26 | — | — | US | claimed |
| US-20260077056-A1 | LINKER-PAYLOAD COMPOUND, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-03-19 | — | — | US | claimed |
| US-12577324-B2 | Antibodies having specificity to HER4 and uses thereof | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-03-17 | — | — | US | claimed |
| WO-2003034903-A2 | PSMA ANTIBODIES AND PROTEIN MULTIMERS | PSMA DEVELOPMENT COMPANY, L.L.C. (US) | 2003-05-01 | — | — | WO | claimed |
| WO-2003033487-A1 | PIPERIDINE- AND PIPERAZINEACETAMINES AS 17BETA HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORPORATION (US) | 2003-04-24 | — | — | WO | claimed |
| WO-2003022835-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORPORATION (US) | 2003-03-20 | — | — | WO | claimed |
| US-20020198216-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | PHARMACOPEIA DRUG DISCOVERY | 2002-12-26 | — | — | US | claimed |
| EP-1229934-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING IMMUNOCONJUGATES AND CHEMOTHERAPEUTIC AGENTS | Immunogen, Inc. (US) | 2002-08-14 | — | — | EP | claimed |
| WO-2002018368-A1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2002-03-07 | — | — | WO | claimed |
| EP-1142583-A1 | ANTITUMOR AGENTS | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 2001-10-10 | — | — | EP | claimed |
| WO-2001024763-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING IMMUNOCONJUGATES AND CHEMOTHERAPEUTIC AGENTS | IMMUNOGEN, INC. (US) | 2001-04-12 | — | — | WO | claimed |
| US-4978744-A | Synthesis of dolastatin 10 | ARIZONA BOARD OF REGENTS (US) | 1990-12-18 | — | — | US | claimed |
| US-4816444-A | ANTITUMOR AGENTS | ARIZONA BOARD OF REGENTS, ARIZONA STATE UNIVERSITY (US) | 1989-03-28 | — | — | US | claimed |